Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

GLAXOSMITHKLINE-PROD. FARMACÊUTICOS, LDA.

NIF 500139962
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €6,885,199 97 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €6,885,199 97 contracts
A2 · Late Publication €15,196,327,339 3,634 contracts
Contract published to BASE more than 10 days after the signing date
LOW €15,196,327,339 3,634 contracts
A5 · Threshold Splitting €54,420,320 116 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €54,420,320 116 contracts
A6 · Low Competition €2,316,411 29 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,316,411 29 contracts
A9 · Price Overrun €750 1 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €750 1 contracts
A9 · Abnormal Price Reduction €19,131,426,210 2,379 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €19,131,426,210 2,379 contracts
C3 · Missing Mandatory Fields €10,575,908 98 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,575,908 98 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

481
€1,229,509,549
70
€725,190,760
70
€715,608,787
77
€670,494,081
180
€610,415,243
289
€605,978,878
266
€589,601,741
109
€582,256,641
49
€571,735,447
63
€570,728,762
50
€556,981,637
187
€543,261,844
107
€535,502,256
37
€519,052,079
78
€484,305,429
47
€465,486,213
83
€463,565,455
ARS Alentejo, IP
NIF 503148768
108
€439,527,756
112
€438,447,637
87
€438,186,852
Page 1 of 4 · 78 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 29 contracts

Aquisição de MEPOLIZUMAB 100 MG/1 ML SOL INJ CANETA 1 ML SC
PT · 11313641 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€34,813 2025-03-14
ANTIASMATICOS - MEPOLIZUMAB - 6 MESES
PT · 11266164 · Ao abrigo de acordo-qu...
A6 · Low Competition
€331,560 2025-03-07
ANTIASMATICOS
PT · 11246934 · Ao abrigo de acordo-qu...
A6 · Low Competition
€106,382 2025-02-25
Aquisição de FLUTICASONA 125 µG+ SALMETEROL 25 µG SUSP PRESSU INAL RECIP PRESSU 120 DOSE(S)
PT · 11246753 · Ao abrigo de acordo-qu...
A6 · Low Competition
€683 2025-02-18
VACINAS
PT · 11233687 · Ao abrigo de acordo-qu...
A6 · Low Competition
€134,930 2025-02-18
Aquisição Dostarlimab
PT · 11255225 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A2 · Late Publication +1
€168,317 2025-02-17
Fornecimento de Mepolizumab ao HSEIT, EPER.
PT · 11226448 · Ajuste Direto Regime G...
A6 · Low Competition
€170,143 2025-02-13
ANTIASMATICOS - MEPOLIZUMAB
PT · 11099919 · Ao abrigo de acordo-qu...
A6 · Low Competition
€69,802 2024-12-20
CITOTOXICOS - NIRAPARIB
PT · 11063513 · Ao abrigo de acordo-qu...
A6 · Low Competition
€53,212 2024-12-04
IMUNOMODULADORES - BELIMUMAB
PT · 11014711 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,485 2024-11-08
DOSTARLIMAB 50 MG/ML SOL INJ FR 10 ML IV
PT · 11030234 · Ajuste Direto Regime G...
A6 · Low Competition
€33,663 2024-11-08
BEAD20240410 - AQUISIÇÃO DE ANTIASMÁTICOS - MEPOLIZUMAB - 3 MESES
PT · 10977266 · Ao abrigo de acordo-qu...
A6 · Low Competition
€130,879 2024-10-17
Aquisição de 6 unidades de Dostarlimab 50 mg/ml Sol inj Fr 10 ml IV
PT · 10990096 · Ajuste Direto Regime G...
A1 · Repeat Direct Award A6 · Low Competition
€33,663 2024-10-15
BEAD20240394 - AQUISIÇÃO DE ANTIASMÁTICOS - 3 MESES
PT · 10898224 · Ao abrigo de acordo-qu...
A6 · Low Competition
€23,994 2024-09-02
DOSTARLIMAB 50 MG/ML SOL INJ FR 10 ML IV
PT · 11002800 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€117,822 2024-08-22
CITOTOXICOS -NIRAPARIB - 3 MESES
PT · 10867992 · Ao abrigo de acordo-qu...
A6 · Low Competition
€53,212 2024-08-13
C/ BASE NO CPA 2022_173
PT · 10959139 · Ao abrigo de acordo-qu...
A2 · Late Publication A6 · Low Competition
€4,682 2024-08-02
ANTIASMÁTICOS - MEPOLIZUMAB - 1º SEMESTRE
PT · 10756649 · Ao abrigo de acordo-qu...
A6 · Low Competition
€130,879 2024-06-06
2024003686 – Aquisição de medicamentos
PT · 10717066 · Ajuste Direto Regime G...
A6 · Low Competition
€8,725 2024-05-15
BEAD20240234 - AQUISIÇÃO DE IMUNOMODULADORES - BELIMUMAB - 1º SEMESTRE
PT · 10687732 · Ao abrigo de acordo-qu...
A6 · Low Competition
€22,485 2024-04-26
2024002769 – Aquisição de medicamentos
PT · 10670658 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€22,171 2024-03-22
VACINAS
PT · 10609665 · Ao abrigo de acordo-qu...
A6 · Low Competition
€81,682 2024-03-13
IMUNOMODULADORES - BELIMUMAB - 1º SEMESTRE
PT · 10609581 · Ao abrigo de acordo-qu...
A6 · Low Competition
€50,606 2024-03-13
2024001146 – Aquisição de medicamentos
PT · 10684857 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€6,219 2024-03-12
241000120/13559 - VACINAS
PT · 10591462 · Ao abrigo de acordo-qu...
A9 · Abnormal Price Reduction A6 · Low Competition
€3,416 2024-02-29
Aquisição de DOSTARLIMAB 50 MG/ML SOL INJ FR 10 ML IV
PT · 11219136 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€112,211 2024-02-22
aquisição de A.U.E DOSTARLIMAB 500MG
PT · 10902162 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€224,423 2024-02-21
Fornecimento de Mepolizumab ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 10592555 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€154,299 2024-02-15
61/1586/2024 - edicamento Belimumab
PT · 10680829 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€9,052 2024-02-07
Overview
Total Value Won
€19,271,728,200
Contracts Won
5,226
Score 180655 · CRITICAL RISK
NIF
500139962
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • E.L. [P-8d50]
    Gerente
    since 2009-10-28
  • J.A. [P-e4d1]
    Gerente
    since 2026-01-23
  • L.R. [P-109d]
    Gerente
    since 2025-09-08
  • N.D. [P-bd39]
    Gerente
    since 2025-07-02
  • T.A. [P-cb99]
    Gerente
    since 2023-12-19
  • A.C. [P-4384]
    Gerente
    2011-09-02 → 2013-11-05
  • A.V. [P-86ee]
    Gerente
    2009-05-11 → 2011-05-03
  • E.L. [P-8d50]
    Gerente
    until 2018-01-19
  • E.B. [P-0ecb]
    Gerente
    2023-12-19 → 2026-01-23
  • E.M. [P-7f84]
    Gerente
    2015-07-22 → 2018-12-11
  • G.M. [P-e820]
    Gerente
    2020-12-29 → 2025-09-19
  • M.C. [P-993a]
    Gerente
    2013-11-05 → 2015-07-22
  • M.J. [P-b672]
    Gerente
    2015-07-22 → 2020-12-29
  • M.M. [P-1119]
    Gerente
    2021-03-22 → 2025-09-08
  • M.A. [P-3173]
    Gerente
    2021-09-13 → 2023-10-09
  • M.A. [P-e444]
    Gerente
    until 2009-10-28
  • P.M. [P-efa7]
    Gerente
    2011-05-03 → 2011-09-02
  • R.C. [P-c36b]
    Gerente
    2015-07-22 → 2023-12-19
  • R.M. [P-2edd]
    Gerente
    2020-09-14 → 2021-03-22
  • S.Y. [P-ada9]
    Gerente
    2018-05-14 → 2020-09-14
  • T.A. [P-a5a4]
    Gerente
    until 2015-07-22
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned